Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MA, J. Z.
Right arrow Articles by COLLINS, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MA, J. Z.
Right arrow Articles by COLLINS, A. J.
J Am Soc Nephrol 10:610-619, 1999
© 1999 American Society of Nephrology

REGULAR ARTICLES

Hematocrit Level and Associated Mortality in Hemodialysis Patients

JENNIE Z. MA*, JIM EBBEN{dagger}, HONG XIA{dagger} and ALLAN J. COLLINS*

* Division of Nephrology, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota.
{dagger} Nephrology Analytical Services, Minneapolis Medical Research Foundation, Minneapolis, Minnesota.

Correspondence to Dr. Allan J. Collins, Division of Nephrology, University of Minnesota, 825 South Eighth Street, Suite 816, Minneapolis, MN 55404. Phone: 612-347-5811; Fax: 612-347-5878.

Abstract. Although a number of clinical studies have shown that increased hematocrits are associated with improved outcomes in terms of cognitive function, reduced left ventricular hypertrophy, increased exercise tolerance, and improved quality of life, the optimal hematocrit level associated with survival has yet to be determined. The association between hematocrit levels and patient mortality was retrospectively studied in a prevalent Medicare hemodialysis cohort on a national scale. All patients survived a 6-mo entry period during which their hematocrit levels were assessed, from July 1 through December 31, 1993, with follow-up from January 1 through December 31, 1994. Patient comorbid conditions relative to clinical events and severity of disease were determined from Medicare claims data and correlated with the entry period hematocrit level. After adjusting for medical diseases, our results showed that patients with hematocrit levels less than 30% had significantly higher risk of all-cause (12 to 33%) and cause-specific death, compared to patients with hematocrits in the 30% to less than 33% range. Without severity of disease adjustment, patients with hematocrit levels of 33% to less than 36% appear to have the lowest risk for all-cause and cardiac mortality. After adjusting for severity of disease, the impact of hematocrit levels of 33% to less than 36% is vulnerable to the patient sample size but also demonstrates a further 4% reduced risk of death. Overall, these findings suggest that sustained increases in hematocrit levels are associated with improved patient survival.




This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
A. von Drygalski and J. Biller
Anemia in Cystic Fibrosis: Incidence, Mechanisms, and Association With Pulmonary Function and Vitamin Deficiency
Nutr Clin Pract, October 1, 2008; 23(5): 557 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Trivedi, Q. Xiang, and J. P. Klein
Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients
Nephrol. Dial. Transplant., August 5, 2008; (2008) gfn426v1.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. Tomasello
Anemia of Chronic Kidney Disease
Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195.
[Abstract] [PDF]

Home page
 Cleveland Clinic Journal of MedicineHome page
S. G. DEMIRJIAN and S. NURKO
Anemia of chronic kidney disease: When normalcy becomes undesirable
Cleveland Clinic Journal of Medicine, May 1, 2008; 75(5): 353 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Ishani, C. A. Solid, E. D. Weinhandl, D. T. Gilbertson, R. N. Foley, and A. J. Collins
Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1682 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
D. T. Gilbertson, J. P. Ebben, R. N. Foley, E. D. Weinhandl, B. D. Bradbury, and A. J. Collins
Hemoglobin Level Variability: Associations with Mortality
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 133 - 138.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Ishani, H. Guo, D. T. Gilbertson, J. Liu, S. Dunning, A. J. Collins, and R. N. Foley
Time to target haemoglobin concentration (11 g/dl) risk of hospitalization and mortality among incident dialysis patients
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2247 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
W. Sulowicz, F. Locatelli, J.-P. Ryckelynck, J. Balla, B. Csiky, K. Harris, P. Ehrhard, U. Beyer, and on behalf of the PROTOS Study Investigators
Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 637 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. Barany and H.-J. Muller
Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease
Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv10 - iv18.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom
OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD)
Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26.
[Full Text] [PDF]

Home page
 HypertensionHome page
C. M. Boulanger, N. Amabile, A. P. Guerin, B. Pannier, A. S. Leroyer, Z. Mallat, C. Nguyen, A. Tedgui, and G. M. London
In Vivo Shear Stress Determines Circulating Levels of Endothelial Microparticles in End-Stage Renal Disease
Hypertension, April 1, 2007; 49(4): 902 - 908.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Portoles, J. M. Lopez-Gomez, P. Aljama, and on behalf of the MAR Study Group
A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 500 - 507.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. C. Fink, V. D. Hsu, M. Zhan, L. D. Walker, C. D. Mullins, C. Jones-Burton, P. Langenberg, and S. L. Seliger
Center Effects in Anemia Management of Dialysis Patients
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 646 - 653.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
B. D. Bradbury, R. B. Fissell, J. M. Albert, M. S. Anthony, C. W. Critchlow, R. L. Pisoni, F. K. Port, and B. W. Gillespie
Predictors of Early Mortality among Incident US Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 89 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
W. C. Winkelmayer, A. Chandraker, M. Alan Brookhart, R. Kramar, and G. Sunder-Plassmann
A prospective study of anaemia and long-term outcomes in kidney transplant recipients
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3559 - 3566.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. Lahera, M. Goicoechea, S. G. de Vinuesa, P. Oubina, V. Cachofeiro, F. Gomez-Campdera, R. Amann, and J. Luno
Oxidative Stress in Uremia: The Role of Anemia Correction
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S174 - S177.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. Locatelli, L. Del Vecchio, and P. Pozzoni
Anemia and Cardiovascular Risk: The Lesson of the CREATE Trial
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S262 - S266.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. B. Drueke, F. Locatelli, N. Clyne, K.-U. Eckardt, I. C. Macdougall, D. Tsakiris, H.-U. Burger, A. Scherhag, and the CREATE Investigators
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
N. Engl. J. Med., November 16, 2006; 355(20): 2071 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. L. Roberts, R. N. Foley, E. D. Weinhandl, D. T. Gilbertson, and A. J. Collins
Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels
Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1652 - 1662.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. Paoletti and G. Cannella
Update on Erythropoietin Treatment: Should Hemoglobin Be Normalized in Patients with Chronic Kidney Disease?
J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S74 - S77.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
F. K. Port, R. L. Pisoni, J. Bommer, F. Locatelli, M. Jadoul, G. Eknoyan, K. Kurokawa, B. J. Canaud, M. P. Finley, and E. W. Young
Improving Outcomes for Dialysis Patients in the International Dialysis Outcomes and Practice Patterns Study
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 246 - 255.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. S. Parfrey, R. N. Foley, B. H. Wittreich, D. J. Sullivan, M. J. Zagari, D. Frei, and for the Canadian European Study
Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2180 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. Tolman, D. Richardson, C. Bartlett, and E. Will
Structured Conversion from Thrice Weekly to Weekly Erythropoietic Regimens Using a Computerized Decision-Support System: A Randomized Clinical Study
J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1463 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Weiss and L. T. Goodnough
Anemia of Chronic Disease
N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. V.R. Murthy, D. A. Molony, and A. G. Stack
Survival Advantage of Hispanic Patients Initiating Dialysis in the United States Is Modified by Race
J. Am. Soc. Nephrol., March 1, 2005; 16(3): 782 - 790.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Gupta, Y. Birnbaum, and B. F. Uretsky
The renal patient with coronary artery disease: Current concepts and dilemmas
J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1343 - 1353.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
G. M. T. Hare, K. M. Hum, S. Y. Kim, A. Barr, A. J. Baker, and C. D. Mazer
Increased Cerebral Tissue Oxygen Tension After Extensive Hemodilution with a Hemoglobin-Based Oxygen Carrier
Anesth. Analg., August 1, 2004; 99(2): 528 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
W. H. Kazmi, G. T. Obrador, S. S. Khan, B. J. G. Pereira, and A. T. Kausz
Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis
Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1808 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. I. Feldman, M. Joffe, B. Robinson, J. Knauss, B. Cizman, W. Guo, E. Franklin-Becker, and G. Faich
Administration of Parenteral Iron and Mortality among Hemodialysis Patients
J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1623 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. C. Winkelmayer, R. Kewalramani, M. Rutstein, S. Gabardi, T. Vonvisger, and A. Chandraker
Pharmacoepidemiology of Anemia in Kidney Transplant Recipients
J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1347 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Jadoul, Y. Vanrenterghem, M. Foret, R. Walker, and S. J. Gray
Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients
Nephrol. Dial. Transplant., April 1, 2004; 19(4): 898 - 903.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano
Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine
Arch Intern Med, February 9, 2004; 164(3): 262 - 276.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, R. L. Pisoni, C. Combe, J. Bommer, V. E. Andreucci, L. Piera, R. Greenwood, H. I. Feldman, F. K. Port, and P. J. Held
Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Nephrol. Dial. Transplant., January 1, 2004; 19(1): 121 - 132.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. D. Roger, L. P. McMahon, A. Clarkson, A. Disney, D. Harris, C. Hawley, H. Healy, P. Kerr, K. Lynn, A. Parnham, et al.
Effects of Early and Late Intervention with Epoetin {alpha} on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial
J. Am. Soc. Nephrol., January 1, 2004; 15(1): 148 - 156.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. J. Snyder, R. N. Foley, D. T. Gilbertson, E. F. Vonesh, and A. J. Collins
Hemoglobin Levels and Erythropoietin Doses in Hemodialysis and Peritoneal Dialysis Patients in the United States
J. Am. Soc. Nephrol., January 1, 2004; 15(1): 174 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. F. Griffith, D. N. Reddan, P. S. Klassen, and W. F. Owen
Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease?
Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2479 - 2482.
[Full Text] [PDF]

Home page
 HypertensionHome page
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al.
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Hypertension, November 1, 2003; 42(5): 1050 - 1065.
[Full Text] [PDF]

Home page
 CirculationHome page
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al.
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Circulation, October 28, 2003; 108(17): 2154 - 2169.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. F. Owen Jr.
Patterns of Care for Patients with Chronic Kidney Disease in the United States: Dying for Improvement
J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S76 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. R. Nissenson, L. T. Goodnough, and R. W. Dubois
Anemia: Not Just an Innocent Bystander?
Arch Intern Med, June 23, 2003; 163(12): 1400 - 1404.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
I. C. Macdougall
CREATE: new strategies for early anaemia management in renal insufficiency
Nephrol. Dial. Transplant., June 1, 2003; 18(suppl_2): ii13 - ii16.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. M. Mancini, S. D. Katz, C. C. Lang, J. LaManca, A. Hudaihed, and A.-S. Androne
Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure
Circulation, January 21, 2003; 107(2): 294 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Valderrabano, W. H. Horl, I. C. Macdougall, J. Rossert, B. Rutkowski, and J.-P. Wauters
PRE-dialysis survey on anaemia management
Nephrol. Dial. Transplant., January 1, 2003; 18(1): 89 - 100.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. S. Kinchen, J. Sadler, N. Fink, R. Brookmeyer, M. J. Klag, A. S. Levey, and N. R. Powe
The Timing of Specialist Evaluation in Chronic Kidney Disease and Mortality
Ann Intern Med, September 17, 2002; 137(6): 479 - 486.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Coladonato, D. L. Frankenfield, D. N. Reddan, P. S. Klassen, L. A. Szczech, C. A. Johnson, and W. F. Owen Jr.
Trends in Anemia Management among US Hemodialysis Patients
J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1288 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. Oserman, S. Watnick, T. F. Griffith, J. A. Coladonato, W. F. Owen, Jr, J. A. Vassalotti, R. Manfredini, B. Boari, O. la Cecilia, F. Portaluppi, et al.
Does Time of Day of Hemodialysis Affect Survival?
JAMA, March 13, 2002; 287(10): 1262 - 1264.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. I. Feldman, J. Santanna, W. Guo, H. Furst, E. Franklin, M. Joffe, S. Marcus, and G. Faich
Iron Administration and Clinical Outcomes in Hemodialysis Patients
J. Am. Soc. Nephrol., March 1, 2002; 13(3): 734 - 744.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. J. COLLINS, S. LI, W. ST. PETER, J. EBBEN, T. ROBERTS, J. Z. MA, and W. MANNING
Death, Hospitalization, and Economic Associations among Incident Hemodialysis Patients with Hematocrit Values of 36 to 39%
J. Am. Soc. Nephrol., November 1, 2001; 12(11): 2465 - 2473.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, L. D. Vecchio, and S. Andrulli
The modality of dialysis treatment: does it influence the response to erythropoietin treatment?
Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1971 - 1974.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. SHOJI, M. EMOTO, K. SHINOHARA, R. KAKIYA, Y. TSUJIMOTO, H. KISHIMOTO, E. ISHIMURA, T. TABATA, and Y. NISHIZAWA
Diabetes Mellitus, Aortic Stiffness, and Cardiovascular Mortality in End-Stage Renal Disease
J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2117 - 2124.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K.-U. Eckardt
After 15 years of success--perspectives of erythropoietin therapy
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1745 - 1749.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. T. KAUSZ, S. S. KHAN, R. ABICHANDANI, W. H. KAZMI, G. T. OBRADOR, R. RUTHAZER, and B. J. G. PEREIRA
Management of Patients with Chronic Renal Insufficiency in the Northeastern United States
J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1501 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. S. Silverberg, D. Wexler, D. Sheps, M. Blum, G. Keren, R. Baruch, D. Schwartz, T. Yachnin, S. Steinbruch, I. Shapira, et al.
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1775 - 1780.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. O'Riordan and R. N. Foley
When should we start erythropoietin therapy?
Nephrol. Dial. Transplant., May 1, 2001; 16(5): 891 - 892.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. J. MIDDLETON, P. S. PARFREY, and R. N. FOLEY
Left Ventricular Hypertrophy in the Renal Patient
J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1079 - 1084.
[Full Text]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, S. Andrulli, F. Pecchini, L. Pedrini, S. Agliata, L. Lucchi, M. Farina, V. La Milia, C. Grassi, M. Borghi, et al.
Effect of high-flux dialysis on the anaemia of haemodialysis patients
Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1399 - 1409.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. S. Silverberg, D. Wexler, M. Blum, G. Keren, D. Sheps, E. Leibovitch, D. Brosh, S. Laniado, D. Schwartz, T. Yachnin, et al.
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1737 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Zoccali
Cardiovascular risk in uraemic patients--is it fully explained by classical risk factors?
Nephrol. Dial. Transplant., April 1, 2000; 15(4): 454 - 457.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. MORENO, D. SANZ-GUAJARDO, J. M. LOPEZ-GOMEZ, R. JOFRE, and F. VALDERRABANO
Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients
J. Am. Soc. Nephrol., February 1, 2000; 11(2): 335 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Fishbane, J. K. Maesaka, and S. K. Mittal
Is there material hazard to treatment with intravenous iron?
Nephrol. Dial. Transplant., November 1, 1999; 14(11): 2595 - 2598.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
H. XIA, J. EBBEN, J. Z. MA, and A. J. COLLINS
Hematocrit Levels and Hospitalization Risks in Hemodialysis Patients
J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1309 - 1316.
[Abstract] [Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673